Usuda Daisuke, Furukawa Daiki, Imaizumi Rikako, Ono Rikuo, Kaneoka Yuki, Nakajima Eri, Sugawara Yuto, Shimizu Runa, Sakurai Riki, Matsubara Shun, Tanaka Risa, Suzuki Makoto, Shimozawa Shintaro, Hotchi Yuta, Osugi Ippei, Katou Risa, Ito Sakurako, Mishima Kentaro, Kondo Akihiko, Mizuno Keiko, Takami Hiroki, Komatsu Takayuki, Nomura Tomohisa, Sugita Manabu
Department of Emergency and Critical Care Medicine, Juntendo University Nerima Hospital, Nerima 177-8521, Tokyo, Japan.
Department of Sports Medicine, Faculty of Medicine, Juntendo University, Bunkyo 113-8421, Tokyo, Japan.
World J Clin Cases. 2025 Oct 16;13(29):108582. doi: 10.12998/wjcc.v13.i29.108582.
(formerly ) is a hyaline hyphomycete with a ubiquitous distribution. In the last decade this fungus has been increasingly found as the causal agent of infections in humans and other vertebrates. It is an emerging opportunistic pathogen and is increasingly reported, and can cause a wide spectrum of clinical manifestations, especially among immunocompromised patients or following surgical procedures. The pathogenic mechanisms are not yet fully understood. Ocular and cutaneous/subcutaneous infections are the most familiar clinical presentations, and these can also cause disseminated infections. Early and accurate species identification and susceptibility testing are vital. In general, surgical debridement combined with antifungal drug therapy, or the correction of predisposing factors, are usually required to obtain improvement. Infections present a therapeutic challenge, as they have intrinsic resistance to many antifungal agents, but voriconazole and posaconazole are good activity. The overall mortality was 22% and death was attributed to the infection in 46% of cases. Accurate diagnoses can be achieved through newer molecular biological techniques, and these can lead to appropriate management of infections due to this organism. Future studies should ideally aim to elucidate pathogenesis and determine more effective diagnoses and effective antifungal treatment.
（以前）是一种分布广泛的透明丝孢菌。在过去十年中，这种真菌越来越多地被发现是人类和其他脊椎动物感染的病原体。它是一种新兴的机会致病菌，报告越来越多，可引起广泛的临床表现，尤其是在免疫功能低下的患者或手术后。其致病机制尚未完全了解。眼部和皮肤/皮下感染是最常见的临床表现，这些感染也可引起播散性感染。早期准确的菌种鉴定和药敏试验至关重要。一般来说，通常需要手术清创联合抗真菌药物治疗，或纠正易感因素才能取得改善。感染带来了治疗挑战，因为它们对许多抗真菌药物具有固有耐药性，但伏立康唑和泊沙康唑具有良好的活性。总体死亡率为22%，46%的病例死亡归因于感染。通过更新的分子生物学技术可以实现准确诊断，这可以导致对由这种生物体引起的感染进行适当管理。未来的研究理想情况下应旨在阐明发病机制并确定更有效的诊断方法和有效的抗真菌治疗。
